Curious about today's AI digest?ai-tldr.dev
Pomegra LogoPomegra

Daily Digest

BriefMarket · bullishMedium impact
Esc
Chart of 2026 biotech M&A deal values showing record pace of acquisitions above $1B
Photo: Life Science Daily

Eli Lilly Stock Rises 43% in 2026 on Record $31B Acquisition Spree

BioBucks2 min read6 sources

Why is Eli Lilly stock rising in 2026?

Eli Lilly (LLY) stock rose about 43% in 2026 to $1,153, driven by over $31B spent on 13 acquisitions expanding beyond GLP-1 drugs into oncology, immunology, and neuroscience.

Key numbers

LLY Stock YTD 2026+43%to ~$1,153 per share
LLY 2026 M&A Total~$31Bacross 13 acquisitions
Sector Biotech M&A 2026 YTD$194.1B+73% vs 2025 full year ($112B)
Largest LLY Deal 2026$7.8BCentessa Pharmaceuticals — sleep medicine and neuroscience
Avg Biotech Deal Size 2026$527M+44% vs 2025 average of $365M

What happened

Eli Lilly (LLY) stock rose about 43% in 2026 to $1,153, driven by over $31B spent on 13 acquisitions expanding beyond GLP-1 drugs into oncology, immunology, and neuroscience. The buying spree began in January with Ventyx Biosciences ($1.2B, inflammation) and peaked in spring with Centessa Pharmaceuticals ($7.8B, sleep medicine) and Kelonia Therapeutics ($7.0B, cancer cell therapy). Later deals pushed into mental health — AtaiBeckley ($2.8B, July) — and autoimmune disease — Merida Biosciences ($2.9B, August). The wider industry has kept pace: global biotech M&A reached $194B through mid-September, more than 70% above 2025's full-year total of $112B.

Why it matters

Eli Lilly's deal spree matters because the entire pharma industry faces a looming patent cliff — key drugs lose exclusivity by 2030, threatening an estimated $230B of annual industry revenue — and companies must buy tomorrow's treatments today. Lilly in particular is hedging against the day GLP-1 weight-loss drugs face generic competition, by staking out cancer, brain disorders, and autoimmune diseases. The $194B sector-wide M&A wave signals an industry-wide arms race to fill pipelines before the remaining independent biotechs are absorbed.

Who this affects

Marketbullish
Medium impact
Biotech sector broadly gains; pharma ETF investors benefit.
Companybullish
High impact
LLY widens its pipeline, reducing long-term GLP-1 reliance.
Competitorsmixed
Medium impact
AbbVie, Pfizer feel pressure to match Lilly's M&A pace.
Industrymixed
High impact
Fewer independent biotechs remain as M&A absorbs targets fast.

Eli Lilly vs AbbVie, Pfizer, Novo Nordisk

Eli LillyLLY$1.03T+52%28x$31B+
AbbVieABBV$466B+20%17x$10.9B
PfizerPFE$158B+15%10x—
Novo NordiskNVO$191B-26%14x—

As of 2026-09-18

How we got here

  1. Ventyx Biosciences acquired for $1.2B, Lilly's first 2026 deal

  2. Centessa Pharmaceuticals closes at $7.8B, Lilly's largest 2026 buy

  3. Kelonia Therapeutics announced at $7.0B for in-vivo cancer therapy

  4. AtaiBeckley acquired for $2.8B, entering mental-health drug development

  5. Merida Biosciences announced as 13th 2026 acquisition, up to $2.9B

What to watch

  • Merida Biosciences deal close pending regulatory clearanceQ4 2026
  • Full-year 2026 biotech M&A tally vs all-time annual recordsQ4 2026
  • GLP-1 competitive pressure from Novo Nordisk and pipeline rivals2026-12-31

Educational content only. Not investment advice.

More briefsAll briefs →